This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field.
As a result, drug developers make better decisions more quickly (removing 50% of study timeline whitespace) to bring new therapies to market faster. As risks are identified, customized action plans are created and provided to clinical teams to keep studies on track.
Cell and gene therapy (CGT) studies are rapidly gaining momentum in the Asia-Pacific region, fueled by growing patient demand and a thriving ecosystem of innovation. In China, the high incidence of solid tumors is driving an urgent need for advanced therapies, spurring the push for new treatment approaches.
As our understanding of the underlying biology of disease grows more sophisticated, emerging therapies operate on increasingly complex biopathological systems and mechanisms. Safety biomarkers account for adverse effects of a therapy under study. There are several types of biomarkers to consider.
For clinicalresearch professionals, this journey often involves reconciling differing feedback from regulatory agencies, each with unique standards, priorities, and expectations. Additionally, consider the locations of your trial; if it is multiregional, you can start planning for your overall product approval strategy.
Breaking through research barriers Challenge #1: Small groups of patients Rare diseases impact a small number of individuals, making it difficult to recruit enough participants for clinical trials. Developing effective ECs requires more than just matching clinical trial inclusion and exclusion criteria within the RWD source.
This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.
In preparation for World Orphan Drug Congress Europe, we interviewed Nathan Chadwick, Senior Director, Therapeutic Strategy Lead, Rare Disease, and Derek Ansel, MS, LCGC, Vice President, Therapeutic Strategy Lead, Rare Disease, to hear their insights into the current progress in rare disease research and their hopes for 2025.
In the clinicalresearch space, GxP is a set of quality regulations and guidelines designed to establish the safety, efficacy, and integrity of pharmaceuticals, medical devices, and clinical trials. This blog explores key concepts, regulations, and the importance of GxP in delivering successful clinical trials.
The drug development industry faces rising costs and increasingly complex protocols as top challenges, with 49% of developers citing costs as their primary concern and 39% pointing to protocol complexity as a key hurdle, according to a recent survey of 150 drug developers worldwide by the PPD clinicalresearch business of Thermo Fisher Scientific.
Gene therapyresearch is booming in the clinical setting. In this blog, we summarize the growth, risks, and regulatory requirements for gene therapyresearch. We also discuss how a centralized biosafety review process can benefit this type of research.
The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.
The discussions at the conference shed light on innovative approaches to enhance long-term outcomes for patients, focusing on combination therapies that not only aid in weight loss but also help preserve muscle mass, an essential component of healthy body composition.
The enterprise of delivering life-changing medicines to patients involves a complex ecosystem, and in many ways, three key players reside at the core: drug sponsors, the contract research organizations (CROs) that support them and the clinicalresearch sites directly engaging with patients in the trial. We can help.
The Food and Drug Administration (FDA) recently released new guidance regarding cellular and gene therapyproducts, one of which may significantly impact early-phase clinical trials of such products. Instead, they will focus on information specific to that product version.
Development of cell and gene therapies is growing rapidly, given the major advances in genomic technologies and increasing scientific understanding of genetic regulation and immunology. This blog will outline three characteristics of a successful nonclinical program to support entry into clinical trials for a cell or gene therapyproduct.
This significance and focus are ever more apparent when the starting cellular material is imperative to drug product success. Within cell therapyclinical trials, apheresis collections contribute to the specific constituents of the given therapy.
clinical operations, pharmacovigilance, etc.) across protocols, medicinal products, a portfolio of studies or the entire company. Need to complement your current clinical development capabilities to meet timelines and stay within budget? Just as no two biotech companies are alike, neither are any two hybrid solutions the same.
The PPD clinicalresearch business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.
Food and Drug Administration (FDA)-approved therapies for treating PAH were primarily vasodilators, designed to overcome the imbalance between vasoactive and vasodilator mediators and to restore endothelial cell function. Complexity: PAH trial sites are complex and require highly experienced clinicians, researchers and support staff.
The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinicalresearchers to discuss the latest advancements and challenges in oncology research. Check out this webinar on navigating the landscape of oncology clinical trials.
In late August, Pfizer announced it was investing an additional $500 million into its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. Ricci told BioSpace the company has been “investing heavily in gene therapy and in the Raleigh-Durham Research Triangle Park area.” Rendering of Durham location.
Gene therapyresearch is exciting and full of promise, but because of the risks involved, it’s also highly regulated, requiring an institutional biosafety committee (IBC) to provide additional oversight and risk assessment. The IBC’s membership roster is therefore unique to the individual research location it oversees.
The PPD clinicalresearch business of Thermo Fisher Scientific has surveyed more than 150 drug developers around the globe to gather annual data on trends in pharmaceutical research and development. In contrast, study design and product registration are the least likely to be outsourced.
Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow. What Does the Future of Gene Editing Hold?
QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity. Integrating SolveBio’s technology with QuartzBio’s existing portfolio helps us accomplish that.”
Certain skin products. Avoid using scented products, as they may irritate the skin further. If you are unsure which products to use, consult with a dermatologist or doctor. Find a Prurigo Nodularis Clinical Trial at Olympian ClinicalResearch. Rough fabrics like wool or polyester.
We also leverage existing clinical gene expression data from different subsets of molecularly profiled cancer patients, who differ in a certain aspect of disease or response to a particular therapy. We are pleased that to date our lead product candidate has aligned DCI profiles as expected.
In addition, clinicalresearch may provide new information and breakthrough treatments. . They may be able to recommend specific products or prescribe medication. Moreover, be aware of soaps, detergents, or other products that may trigger your child’s eczema flare-ups and avoid using them.
BY RACHEL COE, MSC | FEB 7, 2024 10:21 PM CST The Bespoke Gene Therapy Consortium A collaborative effort, the Bespoke Gene Therapy Consortium (BGTC) was launched in October 2021 to “accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease.”
However, dermatologists have had success treating the condition with therapies that aim to: Reduce flare-ups. This may include products with benzoyl peroxide or non-irritating, non-comedogenic cleansers. ClinicalResearch on Hidradenitis Suppurativa. For these people, clinicalresearch studies may be an option.
After that, I spent over a decade at a large instrument and genomics company working in, and then leading, research and development. Our customers use our products, tools and services to make a positive impact in health and sustainability. Often, DNA technology is used in the development of new therapies.
Seeking relief at the genetic cause of disease Engaged discussion with the audience followed my joint presentation on this topic with Matthew Fuller, PhD, PMP, Executive Director of Gene TherapyResearch at Ultragenyx. Roughly 80% of rare diseases are due to a known genetic driver.
E&C lawmakers grill directors of FDA medical product centers Wednesday’s House E&C Health Subcommittee Hearing featured an extensive grilling of the leaders of FDA’s three medical products centers: CDER, CBER and CDRH. House of Representatives’ Energy and Commerce (E&C) Committee on Thursday, May 22.
Sarah brings a wealth of experience and a proven track record of advising innovative drug and biologics companies through the intricate landscape of product development and commercialization. Most of all, we are excited to be working alongside someone who shares our passion to bring new therapies to those in need,” notes James E.
The Phase 3 AMEERA-6 study will evaluate the efficacy and safety of Sanofi’s amcenestrant vs tamoxifen for women with estrogen receptor-positive (ER+) breast cancer who were unable to continue their adjuvant aromatase inhibitor (AI) therapy. Adjuvant therapy helps prevent and delay the progression of disease into the later setting.
Clinicalresearch aims to produce knowledge in the service of treating diseases and improving human health. In a just and well-functioning society, the benefits of research would ideally be shared equitably among all social groups, regardless of race, age, gender, or ethnicity. This gives the research community (e.g.,
It can augment preclinical and clinicalresearch through mechanistic and predictive investigations that would otherwise be impossible. Natalizumab is a disease-modifying treatment for RRMS and is used as first- or second-line therapy depending on a patient’s clinical history.
If your company is struggling to hire qualified clinicalresearch associates (CRAs), you’re not alone. A decade-long CRA talent shortage intensified as the COVID-19 pandemic increased strain on the clinicalresearch industry at large.
Vial | Pros and Cons The unprecedented consequences of the COVID-19 pandemic gave rise to the advent of decentralized clinical trials (DCTs), which are studies that use telemedicine and remote or local healthcare professionals to enable participants to join from different locations. billion and now functions as a subsidiary.
Chiauranib as a single agent therapy inhibits the overactive Aurora B pathway existed in and related to molecular mechanism of SCLC, which is an important feature of Chiauranib distinct to other antiangiogenic drugs. Chiauranib has shown pharmacological activity superior to that of other similar drugs in animal studies. Source link.
Laser Treatments for Rosacea Laser therapy stands out as one of the most effective treatments for reducing the redness and visible blood vessels associated with rosacea. Techniques like Intense Pulsed Light ( IPL ) therapy and Broad Band Light ( BBL ) therapy are both effective options offered at Academic Alliance in Dermatology.
These data also support the potential first-line use of LENVIMA plus everolimus, which is already approved in advanced RCC following prior antiangiogenic therapy,” said Dr. Takashi Owa, Vice President, Chief Medicine Creation and Chief Discovery Officer, Oncology Business Group at Eisai. Source link.
Accelerating Clinical Trials in the EU (ACT EU) ACT EU is an initiative designed to transform the initiation, development, and running of clinical trials within the EU. Embracing Advanced Therapies The expansion of new cell and gene therapies, particularly CAR-T and TCR cell therapies, is a notable trend in oncology.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
69 
Let's personalize your content